It is currently Thu Mar 26, 2015 9:24 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Neuren - NZ company

Dear all,

In March it was reported that the US Army were taking up a brain injury drug which was in early trials. The company behind the drug are Neuren. A link to their website is attached.

The company are developing some interesting products relevant to MS (see under Technology and Development Pipeline). Many of the drugs are neuro-protective, but they also have a peptide in development to ...
Read more : Neuren - NZ company | Views : 1305 | Replies : 0

High dose Prednisone - 1250 mg per day

Has anyone been on Copaxone with 1250 mg per day of prednisone? I'm newly diagnosed and have been asked to join a trial. I'm trying to find info about prednisone doses that high and have not had much luck.
Read more : High dose Prednisone - 1250 mg per day | Views : 2735 | Replies : 2

Two oral drugs in trial

Dear all,

The US NMSS website provides info on two oral drugs in trial - FY720 (Dignan has already posted) and another with an unpronouncable name. ... June21.asp

Read more : Two oral drugs in trial | Views : 1629 | Replies : 1

FTY720 Update

Interesting update on FTY720 and their speculation that that it could be available for organ transplant patients -- and therefore also available for off-label use -- by 2007. Also the official results of their phase II trial are being released tomorrow.

Novartis Is Seeking to Beat Serono to First MS Pill

June 20 -- Bloomberg -- Serono, Europe's biggest biotechnology company, Novartis AG, Switzerland's largest drugmaker, and Paris-based Sanofi-Aventis SA are racing to develop the ...
Read more : FTY720 Update | Views : 3160 | Replies : 6

Allon Therapeutics

AL-108 is being tested on Alzheimer's first, but they plan to try it for MS too, so I figure these Phase I safety studies won't have to be done all over again for MS since they are done on healthy adults.

Allon Therapeutics product AL-108 successful in Phase Ia clinical trial

June 15 -- CNW -- Allon Therapeutics, The Neuro Protection Company(TM), announced today that a Phase Ia human clinical trial of the company's first ...
Read more : Allon Therapeutics | Views : 1159 | Replies : 0

Snail toxin

This isn't even in clinical trials, but it sounds promising -- treats neuropathic pain AND accelerates recovery from nerve injury...I hear rumours that it might bring about world peace too...

Snail toxin may help neuropathic pain

June 10 -- UPI -- Melbourne researchers' discovery of a cone snail toxin may help ease pain for neuropathic pain associated with diabetes.

Metabolic Pharmaceuticals Limited says successful results in preclinical trials of the toxin will result in clinical ...
Read more : Snail toxin | Views : 1510 | Replies : 1

Positive results two Phase I/II clinical trials for Tovaxin

Positive interim results of two Phase I/II clinical trials for Tovaxin are released.

Hi, I am Tim,

Here is just a little of my story. So much has happened that I could write a book about my last two years. The vaccine appears to have arrested my disease and has done the same for the other people in the study.

I have two small websites that show a timeline of events. The first one ...
Read more : Positive results two Phase I/II clinical trials for Tovaxin | Views : 2163 | Replies : 2

Update on FTY720

Keep in mind this is from an equity analyst, and they don't cite a source, but I like the sounds of the results of the FTY720 trials...

Biogen Idec's Avonex May Face 'Serious Pressure'

06.03.05 -- Morgan Stanley downgraded Biogen Idec to "equal-weight" from "overweight" and said the biotech firm's Avonex multiple sclerosis drug faces greater long-term risk than previously thought.

Recently released clinical data for FTY720, an experimental MS drug from Novartis (nyse: NVS ...
Read more : Update on FTY720 | Views : 1539 | Replies : 1

Tovaxin Phase I/II Results

The results are good, but the number of patients assessed in this report is tiny! Oh well, they say they are planning to go to Phase II/III in late 2005 or early 2006!

PharmaFrontiers Announces Positive Interim Results of Two Phase I/II Clinical Trials for Multiple Sclerosis

June 3, 2005 -- BUSINESS WIRE -- PharmaFrontiers, a company involved in the development and commercialization of cell therapies, announced that interim results of Tovaxin(TM) in two Multiple ...
Read more : Tovaxin Phase I/II Results | Views : 2598 | Replies : 7

XIAP, a novel target in multiple sclerosis

Interesting article I found on the web

Focis 2005 presentation: XIAP, a novel target in multiple sclerosis
Monday May 16, 9:01 am ET

MONTREAL, May 16 /PRNewswire/ - Aegera Therapeutics Inc. is pleased to announce the presentation of results of a study entitled "Apoptosis Induction as a Therapeutic Intervention to Eliminate Encepalitogenic T cells; Antisense XIAP (AEG35169) in Murine Models of EAE". The study and results were presented at the 5th Annual Meeting of the ...
Read more : XIAP, a novel target in multiple sclerosis | Views : 1521 | Replies : 0


Login  •  Register


Total posts 224317 • Total topics 23419 • Total members 14833

Contact us | Terms of Service